针对LMAN1-MCFD2复合体的RNAi促进了小鼠的抗凝固作用
Siqian Ma1, Boyan Liu1, Hong Du2
1Hematology Department, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215021, China.
Journal of thrombosis and thrombolysis
|September 2, 2024
概括
针对LMAN1和MCFD2的RNA干扰有效地降低了小鼠的凝血因子水平. 这种RNAi疗法显示出作为一种新型抗凝剂策略的前景,尽管出血风险需要进一步评估.
科学领域:
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 凝血因子V (FV) 和VIII (FVIII) 的联合缺陷是一种罕见的出血疾病,与LMAN1或MCFD2基因变异有关.
- 抑制LMAN1-MCFD2复合体以降低FVIII水平是一种潜在的新型抗凝剂方法.
研究的目的:
- 研究针对LMAN1和MCFD2进行抗凝的RNA干扰 (RNAi) 的治疗潜力.
- 通过抑制LMAN1-MCFD2复合体来降低FVIII水平,开发一种新的抗凝固疗法.
主要方法:
- 设计和选针对LMAN1或MCFD2转录的交叉同源siRNA序列.
- 化学修改的最佳siRNAs与N-乙糖氨酸 (GalNAc) 针对性肝脏输送.
- 评估了小鼠的LMAN1和MCFD2表达,凝血功能 (APTT),FVIII活性和出血.
主要成果:
- GalNAc结合的siRNAs (GalNAc-LMAN1,GalNAc-MCFD2) 证明了对LMAN1和MCFD2mRNA的有效和持续的抑制.
- 注射后观察到LMAN1和MCFD2mRNA水平的显著降低.
- 重复施用延长了APTT,显著降低了FVIII活性,但没有显著增加小鼠的出血.
结论:
- 针对LMAN1-MCFD2复合体的RNAi疗法是抗凝固的有效策略.
- 这种方法为开发新的抗凝固药物提供了可行的选择.
- 需要对血栓性模型进行进一步评估,以评估益处和出血风险.
更多相关视频
08:55RNA Interference in Aquatic Beetles as a Powerful Tool for Manipulating Gene Expression at Specific Developmental Time Points
Published on: May 29, 2020
7.7K
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
10.7K
相关概念视频
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
RNA Interference
26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K
